Next |
home / stock / kdmn / kdmn message board
News, Short Squeeze, Breakout and More Instantly...
- REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States - - Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million - - Sanofi acquisition of Kadm...
NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein, in patients with metastatic or locally advanced solid tumors, in addition to other IL-...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Kadmon Holdings, Inc. Skyrockets Amid Entering Definitive Merger Agreement with Sanofi Kadmon Holdings, Inc. (NASDAQ: KDMN) surged 73% in premarket trading after entering...